Literature DB >> 26439951

Serum insulin-like growth factor-I and amyloid beta protein in Alzheimer's disease: relationship with cognitive function.

Ayako Kimoto1, Koji Kasanuki1,2, Ryo Kumagai1,2, Nobuto Shibata1, Yosuke Ichimiya1,2, Heii Arai1.   

Abstract

AIMS: Previous studies have suggested that insulin-like growth factor-I (IGF-I) deficiency may lead to cognitive deficits in neurodegenerative diseases such as Alzheimer's disease. The present study aimed to investigate the possible relationship between cognitive function and concentration of IGF-I or amyloid beta protein (Aβ) in serum in Alzheimer's patients.
METHODS: A total of 81 Japanese patients were enrolled in this study. Concentrations of IGF-I, Aβ42, and Aβ40 in serum were measured. Two neuropsychological tests, Mini-Mental State Examination and Hasegawa's Dementia Scale-Revised (HDS-R), were also performed. Linear correlations among the age, serum IGF-I, serum Aβ42 or Aβ40, Aβ42/Aβ40 ratio, Mini-Mental State Examination or HDS-R total score, and the scores for six HDS-R subscales were analyzed by regression analysis.
RESULTS: IGF-I showed a significant negative correlation with age (β = -0.357, P = 0.002) and a positive correlation with Aβ42/Aβ40 ratio (β = 0.318, P = 0.007). Serum IGF-I and both the Mini-Mental State Examination and the HDS-R total score also correlated (β = 0.505, β = 0.524, P < 0.01). Among the HDS-R subscales, 'Recall' (ρ = 0.379, P < 0.01), 'Verbal fluency' (ρ = 0.360, P < 0.01), and 'Attention and calculation' (ρ = 0.389, P < 0.01) showed significant positive correlations with serum IGF-I.
CONCLUSION: The results, specifically that lower serum IGF-I was associated with cognitive impairment, suggest that metabolism of IGF-I may be involved in the pathogenesis of cognitive deficits in Alzheimer's disease.
© 2015 The Authors. Psychogeriatrics © 2015 Japanese Psychogeriatric Society.

Entities:  

Keywords:  Alzheimer's disease; Aβ40; Aβ42; IGF-I; cognitive function; dementia

Mesh:

Substances:

Year:  2015        PMID: 26439951     DOI: 10.1111/psyg.12149

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  4 in total

1.  Circulating insulin-like growth factor 1 and insulin-like growth factor binding protein-3 level in Alzheimer's disease: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2016-07-05       Impact factor: 3.307

2.  Correlation between parameters related to sarcopenia and gray matter volume in patients with mild to moderate Alzheimer's disease.

Authors:  Shanwen Liu; Yu Zhang; Bo Peng; Chunying Pang; Meng Li; Jiangtao Zhu; Chun-Feng Liu; Hua Hu
Journal:  Aging Clin Exp Res       Date:  2022-09-19       Impact factor: 4.481

3.  Neuroprotective Biomarkers and Cognitive Function in a Long-Term Prospective Population-based Study of Aging US Adults.

Authors:  Adam J Paulsen; Carla R Schubert; Alex Pinto; Cynthia M Carlsson; Richard J Chappell; Mary E Fischer; Barbara E K Klein; Ronald Klein; Michael Y Tsai; Karen J Cruickshanks
Journal:  Alzheimer Dis Assoc Disord       Date:  2020 Jan-Mar       Impact factor: 2.703

4.  Serum insulin-like growth factor 1 (IGF-1) in multiple sclerosis: relation to cognitive impairment and fatigue.

Authors:  Rania S Nageeb; Noha A Hashim; Amal Fawzy
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-09-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.